The test relies on a signature that Almac developed for stratifying breast cancer patients, but which, as the researchers showed, can be used in other cancers as well.
In a recent study in Blood, the researchers showed that a higher allelic burden after transplantation was associated with higher risk of relapse and mortality.
In a new analysis of the trial, researchers concluded that women over the age of 50 with recurrence scores below 25 appear to see no added benefit from adjuvant chemo.
Researchers at the annual meeting of the American Association for Cancer Research discussed their efforts to use genomics to protect patients from radiotherapy toxicity.
The study found that Oncotype DX testing was associated with less frequent chemo use among women at a high clinical risk of recurrence and more frequent chemo in women considered low risk.
The study identified five SNPs significantly associated with five-year progression-free survival and defined risk groups with widely different risks of disease recurrence.
